Re: Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus.
作者信息
Raza Hunain, Bhutta Muhammad E, Siddique Muhammad H
机构信息
Islamic International Medical College, Riphah International University, Rawalpindi, Pakistan.
出版信息
Sultan Qaboos Univ Med J. 2024 Aug;24(3):418-419. doi: 10.18295/squmj.8.2024.050. Epub 2024 Aug 29.
Abstract
摘要
相似文献
1
Re: Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus.关于：维格列汀和瑞格列净作为二甲双胍附加疗法用于2型糖尿病患者的疗效和安全性
Sultan Qaboos Univ Med J. 2024 Aug;24(3):418-419. doi: 10.18295/squmj.8.2024.050. Epub 2024 Aug 29.
2
Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors.维格列汀单药治疗。与其他二肽基肽酶-4抑制剂一样，应避免使用。
Prescrire Int. 2013 May;22(138):121.
3
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.用于治疗2型糖尿病的临床试验中的肠促胰岛素类似物和二肽基肽酶4抑制剂。
Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845.
4
Vildagliptin: a review of its use in type 2 diabetes mellitus.维格列汀：用于 2 型糖尿病的评价。
Drugs. 2010 Nov 12;70(16):2089-112. doi: 10.2165/11206370-000000000-00000.
5
Translating science into clinical practice: focus on vildagliptin in combination with metformin.将科学转化为临床实践：聚焦维格列汀联合二甲双胍
Diabetes Obes Metab. 2009 May;11 Suppl 2:18-26. doi: 10.1111/j.1463-1326.2008.01030.x.
6
Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.维格列汀治疗二甲双胍和磺脲类药物控制不佳的 2 型糖尿病患者的疗效和安全性。
Diabetes Obes Metab. 2014 May;16(5):403-9. doi: 10.1111/dom.12229. Epub 2013 Dec 2.
7
Update: vildagliptin for the treatment of Type 2 diabetes.最新消息：维格列汀用于治疗2型糖尿病。
Expert Opin Investig Drugs. 2008 Jan;17(1):105-13. doi: 10.1517/13543784.17.1.105.
8
Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.维格列汀作为一种附加疗法与二甲双胍联用在治疗中国 2 型糖尿病患者中的疗效和耐受性。
Diabetes Obes Metab. 2012 Aug;14(8):737-44. doi: 10.1111/j.1463-1326.2012.01593.x. Epub 2012 Apr 1.
9
A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.一项比较维格列汀和格列齐特与二甲双胍联合治疗单用二甲双胍血糖控制不佳的 2 型糖尿病患者的疗效和安全性的 52 周、随机研究。
Diabet Med. 2010 Mar;27(3):318-26. doi: 10.1111/j.1464-5491.2010.02938.x.
10
Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study.维格列汀与二甲双胍联合治疗与二甲双胍逐步加量治疗中国 2 型糖尿病患者的疗效和安全性：VISION 研究的设计和原理。
Cardiovasc Diabetol. 2013 Aug 19;12:118. doi: 10.1186/1475-2840-12-118.
本文引用的文献
1
Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus: An open-label comparative study.维格列汀和瑞格列净作为 2 型糖尿病患者二甲双胍联合治疗的疗效和安全性：一项开放标签的比较研究。
Sultan Qaboos Univ Med J. 2024 May;24(2):243-249. doi: 10.18295/squmj.1.2024.006. Epub 2024 May 27.
2
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective.替尔泊肽治疗 2 型糖尿病成人患者：内分泌学视角。
Diabetes Obes Metab. 2023 Jan;25(1):3-17. doi: 10.1111/dom.14831. Epub 2022 Aug 31.
3
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.恩格列净：在 2 型糖尿病中的心血管结局和死亡率。
N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
4
Prevalence of dyslipidemia in adult Indian diabetic patients: A cross sectional study (SOLID).成年印度糖尿病患者血脂异常患病率：一项横断面研究（SOLID）。
Indian J Endocrinol Metab. 2014 Sep;18(5):642-7. doi: 10.4103/2230-8210.139220.
5
Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.随机试验表明，每日两次瑞格列净酯治疗 2 型糖尿病的疗效和安全性。
Diabetes Obes Metab. 2015 Jan;17(1):94-7. doi: 10.1111/dom.12391. Epub 2014 Nov 3.
Zotero 插件